Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Debt to Equity (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Debt to Equity for 10 consecutive years, with $0.56 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 261.85% to $0.56 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.56, a 261.85% increase, with the full-year FY2025 number at $0.56, up 261.85% from a year prior.
  • Debt to Equity was $0.56 for Q4 2025 at Madrigal Pharmaceuticals, up from $0.54 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $5.16 in Q3 2023 to a low of $0.14 in Q2 2024.
  • A 4-year average of $0.96 and a median of $0.28 in 2023 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: plummeted 97.08% in 2024, then soared 261.85% in 2025.
  • Madrigal Pharmaceuticals' Debt to Equity stood at $0.25 in 2022, then rose by 14.1% to $0.28 in 2023, then crashed by 45.3% to $0.16 in 2024, then skyrocketed by 261.85% to $0.56 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Debt to Equity are $0.56 (Q4 2025), $0.54 (Q3 2025), and $0.17 (Q2 2025).